Our Inflammation & Immune Health cluster is based on Glycoprotein Acetylis (GlycA), rather than other inflammatory markers such as tumor Necrosis Factor alpha (TNF-a) or Interleukin-6 (IL-6). GlycA has been shown to be a reliable marker of systemic, low-grade chronic inflammation and has been associated with an increased risk of cardiovascular disease and type II diabetes.
Through our research, we found that GlycA has the strongest correlation with the gut microbiome and is a reliable indicator of a person's metabolic and immune health. But we will continue to research other markers and may choose to include others in the future based on the latest evidence.